CA
NZ
UK
AU
IND
US
The rationale is anEarningsbeat paired with a guidance raise. On August 6, 2026 management lifted full year growth guidance to about 20% from 14% to 16%, set an adjusted EBITDA margin range of 14.8% to 15.0% and added USD 100 million to the buyback. …
Key HighlightsViridian Therapeutics (NASDAQ:VRDN) traded at USD 28.66 in a published screener snapshot on November 5, 2026, up 50.84% in 1 month, 17.7% in 1 week, 24.72% in 3 months and 68.59% in 6 months.The latest session slipped 1.36%, and the stock sits in …
The rationale is a cash flow andBalance Sheetbeat inside a turnaround story, with a strategic review as the swing factor. Net debt fell by USD 335.7 million in the quarter (simple arithmetic on two published numbers), and first half free cash flow is expected …
Key HighlightsEPAM Systems (NYSE:EPAM) traded at USD 159.06 in a published screener snapshot on November 5, 2026, up 15.80% on the day, 20.24% over 1 week and 45.93% over 1 month, inside the USD 2 billion to USD 10 billionMid capbracket.Third quarterRevenuewas USD 1.426 …
Key HighlightsFTI Consulting (NYSE:FCN) was at USD 200.00 in a published screener snapshot on November 5, 2026, up 0.85% on the day, 17.26% over 1 week and 44.26% over 1 month, in the USD 2 billion to USD 10 billionMid capbracket.Record third quarterRevenuewas USD …
Key HighlightsV.F. Corporation (NYSE:VFC) was at USD 20.62 in a published screener snapshot on November 5, 2026, down 1.48% on the day but up 16.43% over 1 week and 43.79% over 1 month, in the USD 2 billion to USD 10 billionMid capbracket.Fiscal second …
No single catalyst was identified for the past month, and no earnings, trial readout or filing dated within the window was confirmed. What can be sourced is the pipeline. Sutacimig, formerly HMB-001, is a subcutaneous bispecific antibody for Glanzmann thrombasthenia. The FDA granted itBreakthrough …
Key HighlightsKyndryl Holdings (NYSE:KD) traded at USD 16.52 in a published screener snapshot on November 5, 2026, up 20.41% in one week and 41.32% in one month, which places it among the best-performing mid caps.Fiscal Q2 2027 results released November 4, 2026 showedRevenueof USD …
The rationale is anUnderwritingturnaround after a drawdown. Specialty Auto posted a combined ratio of about 99.2%, down 4.8 points from 104.0% in the second quarter, and that figure included about USD 23 million of favorable prior-year reserve development. The underlying combined ratio was about …
The rationale is a low-base rebound with improving guidance andCapitalreturn. The company lifted 2026 revenue growth to about 8% from 7%, same club sales growth to about 1.5% to 2% from about 1%, and adjusted EBITDA growth to about 6.5% from 6%. Adjusted EPS …
Please wait processing your request...